Various cancers have been confirmed to be associated with CDCA3 expression, including kidney,[39] bladder,[40] and pancreatic cancer.[41] Also, CDCA3 has been confirmed as a promising target for enhancing the sensitivity of tyrosine kinase inhibitors in patients with TKI-resistant EGFR-mutated NSCLC.[42] In this study, CDCA3 was expressed at higher levels in LUAD tissues than in normal tissues. Here, EGFR is linked to pancreatic neoplasm.